
Nanoviricides (NNVC) Accelerates Mpox Drug Development, Citing Strong Business And Public Health Case
(MENAFN- GetNews) NanoViricides, Inc. (NYSE Amer.: NNVC), a clinical-stage biopharmaceutical company and a pioneer in broad-spectrum antivirals, announced today its accelerated plans to advance its lead drug candidate, NV-387, into Phase II clinical trials …